Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats.
Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P. Galici R, et al. Among authors: dugovic c. Psychopharmacology (Berl). 2011 Apr;214(4):829-41. doi: 10.1007/s00213-010-2092-4. Epub 2010 Nov 18. Psychopharmacology (Berl). 2011. PMID: 21086115
Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.
Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur C, Pudiak CM, Langlois X, Xiao W, Apodaca R, Carruthers NI, Lovenberg TW. Barbier AJ, et al. Among authors: dugovic c. Br J Pharmacol. 2004 Nov;143(5):649-61. doi: 10.1038/sj.bjp.0705964. Epub 2004 Oct 4. Br J Pharmacol. 2004. PMID: 15466448 Free PMC article.
Histamine H3 receptor antagonists: from target identification to drug leads.
Bonaventure P, Letavic M, Dugovic C, Wilson S, Aluisio L, Pudiak C, Lord B, Mazur C, Kamme F, Nishino S, Carruthers N, Lovenberg T. Bonaventure P, et al. Among authors: dugovic c. Biochem Pharmacol. 2007 Apr 15;73(8):1084-96. doi: 10.1016/j.bcp.2006.10.031. Epub 2006 Nov 3. Biochem Pharmacol. 2007. PMID: 17129577
Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor.
Barbier AJ, Aluisio L, Lord B, Qu Y, Wilson SJ, Boggs JD, Bonaventure P, Miller K, Fraser I, Dvorak L, Pudiak C, Dugovic C, Shelton J, Mazur C, Letavic MA, Carruthers NI, Lovenberg TW. Barbier AJ, et al. Among authors: dugovic c. Eur J Pharmacol. 2007 Dec 8;576(1-3):43-54. doi: 10.1016/j.ejphar.2007.08.009. Epub 2007 Aug 14. Eur J Pharmacol. 2007. PMID: 17765221
Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.
Dvorak CA, Apodaca R, Xiao W, Jablonowski JA, Bonaventure P, Dugovic C, Shelton J, Lord B, Miller K, Dvorak LK, Lovenberg TW, Carruthers NI. Dvorak CA, et al. Among authors: dugovic c. Eur J Med Chem. 2009 Oct;44(10):4098-106. doi: 10.1016/j.ejmech.2009.04.049. Epub 2009 May 13. Eur J Med Chem. 2009. PMID: 19524331
Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
Stocking EM, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, Everson A, Fraser I, Jiang X, Leung P, Lord B, Ly KS, Morton KL, Nepomuceno D, Shah CR, Shelton J, Soyode-Johnson A, Letavic MA. Stocking EM, et al. Among authors: dugovic c. Bioorg Med Chem Lett. 2010 May 1;20(9):2755-60. doi: 10.1016/j.bmcl.2010.03.071. Epub 2010 Mar 20. Bioorg Med Chem Lett. 2010. PMID: 20382018
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development.
Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, Everson A, Feinstein MA, Fraser IC, Hoey K, Jiang X, Keith JM, Koudriakova T, Leung P, Lord B, Lovenberg TW, Ly KS, Morton KL, Motley ST, Nepomuceno D, Rizzolio M, Rynberg R, Sepassi K, Shelton J. Letavic MA, et al. Among authors: dugovic c. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4210-4. doi: 10.1016/j.bmcl.2010.05.041. Epub 2010 May 16. Bioorg Med Chem Lett. 2010. PMID: 20561786
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C. Bonaventure P, et al. Among authors: dugovic c. J Pharmacol Exp Ther. 2015 Sep;354(3):471-82. doi: 10.1124/jpet.115.225466. Epub 2015 Jul 15. J Pharmacol Exp Ther. 2015. PMID: 26177655
Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder.
Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, Bertelsen K, Di J, Shelton J, Aluisio L, Dvorak L, Fraser I, Lord B, Nepomuceno D, Ahnaou A, Drinkenburg W, Chai W, Dvorak C, Sands S, Carruthers N, Lovenberg TW. Bonaventure P, et al. Among authors: dugovic c. J Pharmacol Exp Ther. 2012 Aug;342(2):429-40. doi: 10.1124/jpet.112.193995. Epub 2012 May 8. J Pharmacol Exp Ther. 2012. PMID: 22570363 Clinical Trial.
54 results